Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Cardiotoxicity following different doses and schedules of 5-fluorouracil administrationfor malignancy -- a survey of 427 patients.

Maria Vadiaka, Michalis Efremidis, Andreas Zinelis, Christos Kosmas, Nicolas Tsavaris, Dimitris Beldecos, Dimitris Sakelariou, Christos Koufos, George Stamatelos

Med Sci Monit 2002; 8(6): PI51-57

ID: 420798

BACKGROUND: Although cardiotoxicity associated with 5-Fluorouracil (5-FU)administration is infrequent, there are case reports of acute coronary syndromes. We report on patientsundergoing 5-FU chemotherapy who developed cardiac symptoms during its administration.MATERIAL/METHODS:In patients receiving 5-FU who experienced cardiac-related symptoms, ECG and serum cardiac enzyme determinationwere performed. If cardiotoxicity was detected, 5-FU infusion was interrupted, and the patients receivedsublingual nitrates and cardiac monitoring, while patients with more than 2-fold elevated enzyme levelswere monitored in a coronary care unit for at least 72 hours. In cases of acute myocardial infarction,5-FU was terminated.RESULTS: Of 427 patients entering the study, 17 (4%) developed clinical symptomsand ECG abnormalities indicating 5-FU cardiotoxicity. Patients with continuous infusion (c.i.) of 5-FUhad a higher incidence of cardiotoxicity (12/197, 6%) than the remaining (5/235, 2.1%) (p=0.067), butmore toxicity was encountered in patients with c.i. of 5-FU+LV for 24 hours for 5 days than in patientswith the same regimen of 5-FU without LV (p

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree